Cipla launches Nintib to treat idiopathic pulmonary fibrosis; stock ends in green

The pharma major, Cipla Limited announced on Tuesday that it has launched generic Nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF), under the brand name, 'Nintib'. The drug will be made available in the form of 100 mg and 150 mg capsules.

IPF is a rare lung disease that impacts one in ten lakh people and this launch marks a significant milestone in Cipla’s commitment to treat this disease. Cipla’s journey in IPF began in 2010 with the introduction of Pirfenex, the world’s first generic Pirfenidone, and the first-ever approved drug for IPF in India. The company had further reduced the cost of its IPF therapy by 40 per cent in 2013 to provide patient-access to this critical treatment.

In line with its endeavour of enabling effective and affordable management of IPF, Cipla’s Nintib is priced at Rs 69 (100 mg) and Rs 85 (150 mg) per capsule.

IPF has an average survival rate of three to five years if left untreated. It is characterised by scarring in the lungs, wherein the lung tissue becomes stiff and thick.

On Tuesday, the stock of Cipla closed at Rs 764.05 per share, up by 0.03 per cent or Rs 0.20 per share on BSE, against a 0.28 per cent gain in the benchmark index. Its 52-week high is recorded at Rs 829 and the 52-week low is Rs 356.75 on BSE.